|
|
 Previous Article | Table of Contents | Next Article 
The macrocyclic lactone protein kinase C activator, bryostatin 1, either
alone, or in conjunction with recombinant murine granulocyte- macrophage
colony-stimulating factor, protects Balb/c and C3H/HeN mice from the lethal
in vivo effects of ionizing radiation
S Grant, R Traylor, GR Pettit and PS Lin
Department of Pharmacology, Medical College of Virginia, Richmond 23298.
We have examined the in vivo radioprotective effects of the macrocyclic
lactone protein kinase C (PK-C) activator, bryostatin 1, administered
either alone or in conjunction with recombinant murine granulocyte-
macrophage colony-stimulating factor (rmGM-CSF), in Balb/c and C3H/HeN mice
subjected to lethal total body irradiation (TBI). When administered alone
on a divided dose schedule (24 hours and 30 minutes before TBI), rmGM-CSF
(20 micrograms/kg) was ineffective in increasing survival in either strain.
However, in Balb/c mice, bryostatin 1 alone (1 microgram) permitted the
long-term survival (60 days) of 70% of the animals following TBI, and 80%
when administered in conjunction with rmGM-CSF. Bryostatin 1 administered
alone according to this schedule exerted minimal radioprotective effects in
C3H/HeN mice, but, when combined with a subeffective dose of rmGM-CSF,
allowed 50% of the animals to survive. Treatment of Balb/c mice with
bryostatin 1 administered as a single dose 4 hours before TBI resulted in a
20% survival rate, and 45% when administered with rmGM-CSF; corresponding
values for the C3H/HeN strain were 60% and 40%, respectively. Lastly, the
survival rates of Balb/c mice treated with bryostatin 1 administered as a
single dose 4 hours following TBI was 20%, and 25% with rmGM-CSF;
corresponding values were 50% and 25% for C3H/HeN mice. These findings
indicate that the PK-C activator bryostatin 1 exhibits intrinsic in vivo
radioprotective effects in lethally irradiated Balb/c and C3H/HeN mice, and
may, under some circumstances, augment the radioprotective capacity of
rmGM-CSF. They also underscore the critical role that strain differences
and scheduling considerations play in determining the in vivo
radioprotective capacity of bryostatin 1, as well as its interactions with
rmGM-CSF.
Volume 83,
Issue 3,
pp. 663-667,
02/01/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. K. Davidson, S. W. Allen, G. E. Lim, C. M. Anderson, and M. G. Haygood
Evidence for the Biosynthesis of Bryostatins by the Bacterial Symbiont ""Candidatus Endobugula sertula"" of the Bryozoan Bugula neritina
Appl. Envir. Microbiol.,
October 1, 2001;
67(10):
4531 - 4537.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. L. Kelly, Y. Tang, N. Rosensweig, S. Clejan, and B. S. Beckman
Granulocyte-Macrophage Colony-Stimulating Factor Rescues TF-1 Leukemia Cells From Ionizing Radiation-Induced Apoptosis Through a Pathway Mediated by Protein Kinase Calpha
Blood,
July 15, 1998;
92(2):
416 - 424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Bosco, S. Rottschafer, L. S. Taylor, J. R. Ortaldo, D. L. Longo, and I. Espinoza-Delgado
The Antineoplastic Agent Bryostatin-1 Induces Proinflammatory Cytokine Production in Human Monocytes: Synergy With Interleukin-2 and Modulation of Interleukin-2Rgamma Chain Expression
Blood,
May 1, 1997;
89(9):
3402 - 3411.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
